Evidence map›Paper›PMID 35918472›Full record

ArticleAAPS PharmSciTech2022

Sorbitan Monolaurate-Containing Liposomes Enhance Skin Cancer Cell Cytotoxicity and in Association with Microneedling Increase the Skin Penetration of 5-Fluorouracil.

Luiziana Cavalcante Costa Fernandes Crisóstomo, Genuína Stephanie Guimarães Carvalho, Luzia Kalyne Almeida Moreira Leal, Tamara Gonçalves de Araújo, Karina Alexandre Barros Nogueira, Durcilene Alves da Silva, Fábio de Oliveira Silva Ribeiro, Raquel Petrilli, Josimar O Eloy

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Luiziana Cavalcante Costa Fernandes CrisóstomoFaculty of Pharmacy, Dentistry and Nursing, Department of Pharmacy, Fortaleza Universidade Federal do Ceará, Fortaleza, CE, Brazil.
Genuína Stephanie Guimarães CarvalhoFaculty of Pharmacy, Dentistry and Nursing, Department of Pharmacy, Fortaleza Universidade Federal do Ceará, Fortaleza, CE, Brazil.
Luzia Kalyne Almeida Moreira LealFaculty of Pharmacy, Dentistry and Nursing, Department of Pharmacy, Fortaleza Universidade Federal do Ceará, Fortaleza, CE, Brazil.
Tamara Gonçalves de AraújoFaculty of Pharmacy, Dentistry and Nursing, Department of Pharmacy, Fortaleza Universidade Federal do Ceará, Fortaleza, CE, Brazil.
Karina Alexandre Barros NogueiraCenter of Technology, Department of Chemical Engineering, Federal University of Ceará, Fortaleza, Brazil.
Durcilene Alves da SilvaResearch Center on Biodiversity and Biotechnology (BIOTEC), Federal University of Delta do Parnaíba, Parnaíba, PI, Brazil.
Fábio de Oliveira Silva RibeiroResearch Center on Biodiversity and Biotechnology (BIOTEC), Federal University of Delta do Parnaíba, Parnaíba, PI, Brazil.
Raquel PetrilliInstitute of Health Sciences, University of International Integration of the Afro-Brazilian Lusophony- UNILAB, Redenção, CE, Brazil.
Josimar O EloyFaculty of Pharmacy, Dentistry and Nursing, Department of Pharmacy, Fortaleza Universidade Federal do Ceará, Fortaleza, CE, Brazil. josimar.eloy@ufc.br.ORCID http://orcid.org/0000-0003-3219-9969
Universidade Federal do Ceará · BRUniversity for International Integration of the Afro-Brazilian Lusophony · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Squamous cell carcinoma (SCC) represents 20% of cases of non-melanoma skin cancer, and the most common treatment is the removal of the tumor, which can leave large scars. 5-Fluorouracil (5FU) is a drug used in the treatment of SCC, but it is highly hydrophilic, resulting in poor skin penetration in topical treatment. Some strategies can be used to increase the cutaneous penetration of the drug, such as the combination of liposomes containing penetration enhancers, for instance, surfactants, associated with the use of microneedling. Thus, the present work addresses the development of liposomes with penetration enhancers, such as sorbtitan monolaurate, span 20, for topical application of 5-FU and associated or not with the use of microneedling for skin delivery. Liposomes were developed using the lipid film hydration, resulting in particle size, polydispersity index, zeta potential, and 5-FU encapsulation efficiency of 88.08 nm, 0.169, -12.3 mV, and 50.20%, respectively. The presence of span 20 in liposomes potentiated the in vitro release of 5-FU. MTT assay was employed for cytotoxicity evaluation and the IC

Indexed as

FluorouracilSkin NeoplasmsHexosesHumansLiposomesParticle SizeSkinSkin AbsorptionFluorouracilHexosesLiposomessorbitan monolaurate5-FluorouracilLiposomeMicroneedlingNanotechnologyPenetration enhancers

Identifiers

PMID35918472
OpenAlexW4289527380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.